Last reviewed · How we verify
Kaletra Tablets
Kaletra is a combination of lopinavir and ritonavir that inhibits HIV protease to prevent viral replication.
Kaletra is a combination of lopinavir and ritonavir that inhibits HIV protease to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3 trials).
At a glance
| Generic name | Kaletra Tablets |
|---|---|
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | HIV protease inhibitor combination |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Lopinavir is an HIV protease inhibitor that blocks the viral protease enzyme required for HIV maturation and infectivity. Ritonavir is a potent protease inhibitor used at sub-therapeutic doses as a pharmacokinetic booster to inhibit cytochrome P450 metabolism, thereby increasing lopinavir plasma concentrations and half-life. Together, they suppress HIV replication and reduce viral load in infected patients.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- COVID-19 (investigational use in phase 3 trials)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Elevated cholesterol/triglycerides
- Hepatotoxicity
Key clinical trials
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Aluvia (PHASE1)
- Bone and Body Comp: A Sub Study of the SECOND-LINE Study (PHASE4)
- Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (PHASE4)
- Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial (PHASE2, PHASE3)
- Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |